FOLFOX induced PD-L1 tumor cell expression and stimulated CD8+ T cell infiltration in CRC patients indicating anti-PD1 therapy may be used effectively in combination with FOLFOX for CRC treatment [141]. This evidence concerns the gene CD8A and neoplasm.